These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7678972)

  • 1. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
    Moore RL; Fox BS
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    J Clin Invest; 1991 Sep; 88(3):876-84. PubMed ID: 1715888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
    Shirai M; Pendleton CD; Berzofsky JA
    J Immunol; 1992 Mar; 148(6):1657-67. PubMed ID: 1371784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.
    Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA
    J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
    Bergmann C; Stohlmann SA; McMillan M
    Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.
    Martinon F; Gras-Masse H; Boutillon C; Chirat F; Deprez B; Guillet JG; Gomard E; Tartar A; Levy JP
    J Immunol; 1992 Nov; 149(10):3416-22. PubMed ID: 1385524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
    Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A
    Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
    Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ class I-restricted T cells specific for HIV gp160 315-329.
    Moore RL; Fox BS
    Cell Immunol; 1994 Mar; 154(1):43-53. PubMed ID: 7907008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.
    Shirai M; Vacchio MS; Hodes RJ; Berzofsky JA
    J Immunol; 1993 Aug; 151(4):2283-95. PubMed ID: 7688397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein.
    Sastry KJ; Arlinghaus RB
    AIDS; 1991 Jun; 5(6):699-707. PubMed ID: 1715718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
    Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160.
    Nehete PN; Satterfield WC; Matherne CM; Arlinghaus RB; Sastry KJ
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):235-40. PubMed ID: 8471313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.
    Takahashi H; Takeshita T; Morein B; Putney S; Germain RN; Berzofsky JA
    Nature; 1990 Apr; 344(6269):873-5. PubMed ID: 2184369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
    J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.